PHILADELPHIA--(BUSINESS WIRE)--Avid Radiopharmaceuticals, Inc. announced today that new clinical imaging data highlighting the proof of concept results for the Company’s lead technology will be presented at the upcoming 55th Annual Society of Nuclear Medicine (SNM) meeting in New Orleans being held the week of June 16, 2008. The presentations will cover research and development results on several F-18 radiopharmaceuticals being studied by Avid for imaging amyloid plaque, a key pathological component of Alzheimer’s disease (AD), as well as the VMAT2, a marker of dopaminergic synapse density, which is affected in diseases such as Parkinson’s disease (PD) and Dementia with Lewy bodies (DLB).
